Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: This study evaluated the effects of exenatide, a GLP-1 receptor agonist, and sitagliptin, a DPP-4 inhibitor, on 2-h postprandial glucose (PPG), insulin and glucagon secretion, gastric emptying, and caloric intake in T2D patients. METHODS: This double-blind, randomized cross-over, multi-center study was conducted in metformin-treated T2D patients: 54% female; BMI: 33 +/- 5 kg/m(2); HbA(1c): 8.5 +/- 1.2%; 2-h PPG: 245 +/- 65 mg/dL. Patients received exenatide (5 microg BID for 1 week, then 10 microg BID for 1 week) or sitagliptin (100 mg QAM) for 2 weeks. After 2 weeks, patients crossed-over to the alternate therapy. Postprandial glycemic measures were assessed via standard meal test; caloric intake assessed by ad libitum dinner (subset of patients). Gastric emptying was assessed by acetaminophen absorption (Clinicaltrials.gov Registry Number: NCT00477581). RESULTS: After 2 weeks of therapy, 2-h PPG was lower with exenatide versus sitagliptin: 133 +/- 6 mg/dL versus 208 +/- 6 mg/dL, p < 0.0001 (evaluable, N = 61). Switching from exenatide to sitagliptin increased 2-h PPG by +73 +/- 11 mg/dL, while switching from sitagliptin to exenatide further reduced 2-h PPG by -76 +/- 10 mg/dL. Postprandial glucose parameters (AUC, C(ave), C(max)) were lower with exenatide than sitagliptin (p < 0.0001). Reduction in fasting glucose was similar with exenatide and sitagliptin (-15 +/- 4 mg/dL vs. -19 +/- 4 mg/dL, p = 0.3234). Compared to sitagliptin, exenatide improved the insulinogenic index of insulin secretion (ratio exenatide to sitagliptin: 1.50 +/- 0.26, p = 0.0239), reduced postprandial glucagon (AUC ratio exenatide to sitagliptin: 0.88 +/- 0.03, p = 0.0011), reduced postprandial triglycerides (AUC ratio exenatide to sitagliptin: 0.90 +/- 0.04, p = 0.0118), and slowed gastric emptying (acetaminophen AUC ratio exenatide to sitagliptin: 0.56 +/- 0.05, p < 0.0001). Exenatide reduced total caloric intake compared to sitagliptin (-134 +/- 97 kcal vs. +130 +/- 97 kcal, p = 0.0227, N = 25). Common adverse events with both treatments were mild to moderate in intensity and gastrointestinal in nature. CONCLUSIONS: Although this study was limited by a 2-week duration of exposure, these data demonstrate that, exenatide had: (i) a greater effect than sitagliptin to lower postprandial glucose and (ii) a more potent effect to increase insulin secretion and reduce postprandial glucagon secretion in T2D patients. In contrast to sitagliptin, exenatide slowed gastric emptying and reduced caloric intake. These key findings differentiate the therapeutic actions of the two incretin-based approaches, and may have meaningful clinical implications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition to the glucose-lowering actions, GLP-1RA based therapies have been reported to improve both fasting and postprandial lipid profiles in patients with T2D, in particular triglyceride concentrations [104,147,153,176,177].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [176]
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Kahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-002-1009-0 · Cited by 2,166
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Self-citationStandards of Medical Care in Diabetes—2008
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-s012 · Cited by 1,377
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Disordered lipid metabolism and the pathogenesis of insulin resistance.
Savage, D. B., Petersen, K. F., & Shulman, G. I. (2007) · Physiological Reviews · doi:10.1152/physrev.00024.2006 · Cited by 1,107
Göke, R., Fehmann, H. C., Linn, T., Schmidt, H., Krause, M., Eng, J., & Göke, B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36565-2 · Cited by 837 · cited 2×
“2008 Informa UK - Curr Med Res Opin 2008; 24(10) Exenatilde vs.”
Background(2007) · Endocrine Practice · doi:10.4158/ep.13.s1.1 · Cited by 699
Research works printed but not linked: 2
- Gedulin B, 2007, Diabetologia, 50, S239
- 2007, Endocr Pract, 13, 3
Cited by
Items 101–200 of 384
Dalle, S., Burcelin, R., & Gourdy, P. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2012.11.009 · Cited by 60
Incretin agents in type 2 diabetes.
Ross, S. A., & Ékoé, J.-M. (2010) · PubMed Central · Cited by 59
Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance
Tella, S. H., & Rendell, M. S. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018815580257 · Cited by 46
Vergès, B., Bonnard, C., & Renard, E. (2011) · Diabetes & Metabolism · doi:10.1016/j.diabet.2011.07.001 · Cited by 58
“Thus, GLPreceptor agonists are superior to DPP-4 inhibitors in terms of lood glucose reduction [42,43].”
BackgroundTran, S., Retnakaran, R., Zinman, B., & Kramer, C. K. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13137 · Cited by 51
Berg, J. K., Shenouda, S. K., Heilmann, C. R., Gray, A. L., & Holcombe, J. H. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01428.x · Cited by 57
“showed that the molar concentrations of exenatide exceed those of GLP-1 during treatment with sitagliptin [10], which may account for the greater effect of exenatide on postprandial and 24-h glucose concentrations.”
InfluentialSelf-citationD'Alessio, D., Häring, H. ‐., Charbonnel, B., de Pablos‐Velasco, P., Candelas, C., Dain, M. ‐., Vincent, M., Pilorget, V., Yki‐Järvinen, H., & on behalf of the EAGLE Investigators (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12406 · Cited by 56
“This effect has also been shown with the GLP-1 receptor agonists exenatide and lixisenatide, which delay gastric emptying as well as regulate islet hormone release, responses that are effective in maintaining glycaemia after eating [11,22,23].”
ResultLixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects
Becker, R. H. A., Stechl, J., Steinstraesser, A., Golor, G., & Pellissier, F. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2647 · Cited by 49
The Insulin:Glucagon Ratio and the Choice of Glucose-Lowering Drugs
Kalra, S., & Gupta, Y. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0160-4 · Cited by 58
“Relative to the dipeptidyl peptidase inhibitor sitagliptin, exenatide has been shown to increase the IGR [24].”
BackgroundExenatide once weekly for the treatment of type 2 diabetes
Malone, J., Trautmann, M., Wilhelm, K., Taylor, K., & Kendall, D. M. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902766802 · Cited by 55
Willard, F. S., Wootten, D. L., Showalter, A. D., Savage, E. E., FICORILLI, J. V., Farb, T. B., Bokvist, K. B., Alsina‐Fernandez, J., Furness, S. G. B., Christopoulos, A., et al. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.080432 · Cited by 53
“For example, therapeutic levels of the parenterally administered GLP-1 receptor agonist, exenatide, are greater than 8-fold the concentration of endogenous GLP-1(7–36)-NH2/(7–37) (DeFronzo et al., 2008).”
BackgroundPeptides in the regulation of glucagon secretion
Andersen, D. B., & Holst, J. J. (2022) · Peptides · doi:10.1016/j.peptides.2021.170683 · Cited by 43
The Role of Glucagon in the Pathophysiology and Management of Diabetes
Kulina, G., & Rayfield, E. J. (2016) · Endocrine Practice · doi:10.4158/ep15984.ra · Cited by 51
Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects
Cersosimo, E., Gastaldelli, A., Cervera, A., Wajcberg, E., Sriwijilkamol, A., Fernandez, M., Zuo, P., Petz, R., Triplitt, C., Musi, N., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2146 · Cited by 50
Self-citationRemillard, C., MacConell, Li, Pencek, Maggs, & Porter (2013) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s35801 · Cited by 50
SUBBARAYAN, S. K., & Kipnes, M. S. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.580738 · Cited by 49
“DPP-IV inhibitors, by contrast, achieve a more modest twofold augmentation of GLP-1 levels with sitagliptin and do not significantly impact gastric emptying [34].”
BackgroundResultvan Genugten, R. E., van Raalte, D. H., Muskiet, M. H., Heymans, M. W., Pouwels, P. J. W., Ouwens, D. M., Mari, A., & Diamant, M. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0610 · Cited by 46
Christensen, A. S., Hædersdal, S., Støy, J., Storgaard, H., Kampmann, U., Forman, J. L., Seghieri, M., Holst, J. J., Hansen, T., Knop, F. K., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0408 · Cited by 48
“inhibitors inpatientswith type2diabetes (35,36).”
BackgroundSchwartz, S. L., Lai, Y., Xu, J., Abby, S. L., Misir, S., Jones, M. R., & Nagendran, S. (2010) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2009.0049 · Cited by 47
Taste preferences and diet palatability in cats
Pekel, A. Y., Mülazimoğlu, S. B., & Acar, N. (2020) · Journal of Applied Animal Research · doi:10.1080/09712119.2020.1786391 · Cited by 48
Inhibiting or antagonizing glucagon: making progress in diabetes care
Lefèbvre, P. J., Paquot, N., & Scheen, A. J. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12480 · Cited by 44
Evans, M., McEwan, P. C., O'Shea, R., & George, L. (2012) · Diabetes Therapy · doi:10.1007/s13300-012-0015-6 · Cited by 46
“While incretinbased therapies have been compared in clinical trials [7–10, 15, 16], Data comparing their relative efficacy in clinical practice remains limited, particularly when prescribed according to clinical guidelines.”
BackgroundDavidson, J. A. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0469 · Cited by 46
“Mass reproduce only with permission from Mayo Clinic Proceedings. ing levels of both GIP and GLP-1 rapidly decrease.37 This is due to degradation by the ubiquitous cell surface serine peptidase DPP-4 and by glomerular filtration and renal tubular catabolism.40-42 There is significant attenuation of the insulinotropic…”
BackgroundResultInfluentialPractical Use of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Primary Care
Reid, T. S. (2013) · Clinical Diabetes · doi:10.2337/diaclin.31.4.148 · Cited by 43
Basolo, A., Burkholder, J., Osgood, K., Graham, A., Bundrick, S., Frankl, J., Piaggi, P., Thearle, M. S., & Krakoff, J. (2018) · Metabolism · doi:10.1016/j.metabol.2018.03.017 · Cited by 43
“Using an ad libitum dinner paradigm, exenatide administration decreased food intake compared with sitagliptin in subjects with type 2 diabetes [30].”
MethodPleiotropic Actions of the Incretin Hormones
McIntosh, C. H. S., Widenmaier, S. B., & Kim, S. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00002-3 · Cited by 47
Oprea, A. D., Umpierrez, G. E., Sweitzer, B., & Hepner, D. L. (2024) · Anesthesiology · doi:10.1097/aln.0000000000005204 · Cited by 45
The Pharmacologic Basis for Clinical Differences among GLP-1 Receptor Agonists and DPP-4 Inhibitors
Morales, J. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.11.2508 · Cited by 39
“For liraglutide, an immunogenic reaction occurs in , 1% of patients and generally consists of urticaria,67 while anaphylaxis and angioedema have been described in postmarketing reports of exenatide BID.66 Although hypersensitivity reactions were not reported in monotherapy clinical trials with sitagliptin,26,27,52 the…”
BackgroundInfluentialHerzlinger, S., & Horton, E. S. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.11.009 · Cited by 46
“0227; N = 25) compared to sitagliptin 100 mg daily [83].”
BackgroundGutierrez, A. D., Gao, Z., Hamidi, V., Zhu, L., Saint Andre, K. B., Riggs, K., Ruscheinsky, M., Wang, H., Yu, Y., Miller, C., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100813 · Cited by 44
“Changes in insulin and FFA circulation were observed only for the placebo arm, due to gastric emptying, which was also observed in previous studies.(27,28) Consistent with previous reports,(29) glucose only slightly decreased 2 h after exenatide while it increased after placebo (Figures 1A and S1B).”
ResultEarly Improvement of Postprandial Lipemia After Bariatric Surgery in Obese Type 2 Diabetic Patients
Griffo, E., Nosso, G., Lupoli, R., Cotugno, M., Saldalamacchia, G., Vitolo, G., Angrisani, L., Cutolo, P. P., Rivellese, A. A., & Capaldo, B. (2013) · Obesity Surgery · doi:10.1007/s11695-013-1148-z · Cited by 44
Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus
Kennedy, L., & Blonde, L. (2009) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.76.s5.02 · Cited by 45
Addition of incretin therapy to metformin in type 2 diabetes
Scheen, A. J., & Radermecker, R. P. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60399-6 · Cited by 43
Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm
Wilding, J. P. H., Rajeev, S. P., & DeFronzo, R. A. (2016) · Diabetes Care · doi:10.2337/dcs15-3005 · Cited by 43
“The known incretin hormones in humans are glucosedependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) (7-36)amide; GLP-1 is the most biologically active incretin (2).”
BackgroundInfluentialSelf-citationInsights into incretin-based therapies for treatment of diabetic dyslipidemia
Stemmer, K., Finan, B., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.008 · Cited by 43
Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes
Cornell, S. (2012) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2012.01342.x · Cited by 39
“)36Æ03 mg/ dL [)2Æ0 mm], P < 0Æ0001).(6) Exenatide twice-daily had a significantly greater effect on 2-h PPG compared with sitagliptin ()108Æ10 mg/dL [)6Æ0 mm] vs.”
BackgroundResultInfluentialType 2 Diabetes: An Expanded View of Pathophysiology and Therapy
Unger, J., & Parkin, C. G. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.05.2152 · Cited by 42
Pharmacological management of type 2 diabetes: the potential of incretin‐based therapies
Charbonnel, B. H., & Cariou, B. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01317.x · Cited by 42
“This effect was associated with slowed gastric emptying and reduced food intake in the exenatide group [124].”
BackgroundIncretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states
Farr, S., & Adeli, K. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834d68f0 · Cited by 40
“The importance of direct GLP-1R stimulation, particularly, was further revealed as the GLP-1R agonist exenatide caused a larger decrease in postprandial triglycerides than sitagliptin in T2D patients [29].”
BackgroundGlucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
Unger, J. R., & Parkin, C. G. (2011) · Diabetes Therapy · doi:10.1007/s13300-010-0013-5 · Cited by 38
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf036 · Cited by 40
Choosing GLP-1 Receptor Agonists or DPP-4 Inhibitors: Weighing the Clinical Trial Evidence
Reid, T. (2012) · Clinical Diabetes · doi:10.2337/diaclin.30.1.3 · Cited by 35
Confronting the Type 2 Diabetes Epidemic: the Emerging Role of Incretin-Based Therapies
Fonseca, V. A., Zinman, B., Nauck, M. A., Goldfine, A. B., & Plutzky, J. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.04.002 · Cited by 40
Lee, W. C., DeKoven, M., Bouchard, J. R., Massoudi, M., & Langer, J. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12285 · Cited by 39
“com Oral DPP-4is, such as sitagliptin (SITA), alogliptin, saxagliptin and linagliptin, act by preventing the degradation of two incretins, GLP-1 and GIP, but have a reduced glycaemic effect compared with GLP-1 receptor agonists [1,3,4].”
BackgroundComplementing Insulin Therapy to Achieve Glycemic Control
Barnett, A. H. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0039-y · Cited by 38
“Both drugs delay gastric emptying [89, 90] and decrease PPG [89, 91].”
BackgroundWang, T., Gou, Z., Wang, F., Ma, M., & Zhai, S.-D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103798 · Cited by 37
Emerging gliptins for type 2 diabetes
Cahn, A., & Raz, I. (2013) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2013.807796 · Cited by 37
“Patients treated with exenatide demonstrated reduced gastric emptying and reduced caloric intake, effects which were not noted with sitagliptin [13].”
BackgroundIncretin Therapies: Effects Beyond Glycemic Control
Mudaliar, S. R. D., & Henry, R. R. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.014 · Cited by 38
Beyond Glycemic Control: Treating the Entire Type 2 Diabetes Disorder
Brunton, S. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.09.2054 · Cited by 37
“Both drugs produced similar reductions in FPG, but exenatide produced greater reductions in postprandial glucose, postprandial glucagon, and triglycerides, as well as a greater slowing of gastric emptying and reduction in caloric intake.(60)”
Kapitza, C., Zdravkovic, M., Hindsberger, C., & Flint, A. (2011) · Advances in Therapy · doi:10.1007/s12325-011-0044-y · Cited by 36
Incretin-based therapies and cardiovascular risk
Mannucci, E., & Dicembrini, I. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.678940 · Cited by 35
“The possibility that some of the cardiac actions of GLP1 are not mediated by GLP-1R, and that both the ‘active’ (GLP-1[7-36]) and ‘inactivated’ (GLP-1[9-36]) forms of the hormone are cardioprotective, has some relevant clinical implications.”
BackgroundViolante, R., Oliveira, J. H. A., Yoon, K. ‐., Reed, V. A., Yu, M. B., Bachmann, O. P., Lüdemann, J., & Chan, J. Y. C. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03624.x · Cited by 35
The Role of Incretin Therapy at Different Stages of Diabetes
Cernea, S. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.323 · Cited by 35
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes
Koška, J., Sands, M. A., Burciu, C., & Reaven, P. D. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114562411 · Cited by 35
Aguilar, R. B. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.04.008 · Cited by 34
Comparison of liraglutide versus other incretin‐related anti‐hyperglycaemic agents
Blonde, L., & Montanya, E. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01575.x · Cited by 34
“In head-to-head trials, exenatide taken BID lowered PPG to a greater degree than did sitagliptin and liraglutide [15,45].”
BackgroundGlucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
Son, J. W., & Lim, S. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1940 · Cited by 33
“periments, it has been reported that GLP-1 may be effective in improving inflammation [27,28], postprandial hyperlipidemia [29,30], endothelial cell dysfunction [31], and oxidative stress [32], as well as protecting β-cells [33,34].”
BackgroundGLP-1 receptor agonists or DPP-4 inhibitors: How to guide the clinician?
Scheen, A. J. (2013) · Annales d Endocrinologie · doi:10.1016/j.ando.2012.06.002 · Cited by 33
Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitus
Nisal, K., Kela, R., Khunti, K., & Davies, M. J. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-152 · Cited by 33
“Vomiting was experienced by 24% of patients treated with exenatide and 3% of patients treated with sitagliptin [31].”
BackgroundMethodResultInfluentialBoland, C. L., DeGeeter, M., Nuzum, D. S., & Tzefos, M. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r444 · Cited by 35
“Effects of glucagon and glucagon-like peptide-1-(7-36) amide on C cells from rat thyroid and medullary thyroid carcinoma CA-77 cell line.”
BackgroundGenovese, S., Mannucci, E., & Ceriello, A. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0499-6 · Cited by 33
“Non-Glycemic Effects Effects on Body Weight Both exenatide formulations, ExeBID and ExeOW, were demonstrated to be negative regulators of appetite and food intake, and these effects result in an appreciable body weight reduction [8, 29].”
BackgroundTriplitt, C. L., Solis‐Herrera, C., Cersósimo, E., Abdul‐Ghani, M. A., & DeFronzo, R. A. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1114098 · Cited by 34
Self-citationJessen, L., Aulinger, B. A., Hassel, J. L., Roy, K. J., Smith, E. P., Greer, T. M., Woods, S. C., Seeley, R. J., & D'Alessio, D. A. (2012) · Endocrinology · doi:10.1210/en.2012-1358 · Cited by 29
Scheen, A. J. (2011) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2011.10.007 · Cited by 31
“In a trial comparing short-term 2-week treatment with exenatide (5 μg twice daily for 1 week, then 10 μg twice daily for 1 week) versus sitagliptin 100 mg once daily, the results were better after treatment with exenatide, as measured by several variables: lowering postprandial glucose, increasing insulin levels, decr…”
MethodOhlsson, L., Alsalim, W., Carr, R. D., Tura, A., Pacini, G., Mari, A., & Åhrén, B. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12062 · Cited by 31
“This may be surprising as it is well-known that GLP-1 inhibits glucagon secretion [25,26].”
BackgroundOlurishe, C. O., Kwanashie, H. O., Zezi, A. U., DANJUMA, N. M., & Mohammed, B. (2016) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2016.10.065 · Cited by 31
Approach to the patient with thyroid nodules: considering GLP-1 receptor agonists
Kelly, C. A., & Sipos, J. A. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae722 · Cited by 30
Alba, M., Åhrén, B., Inzucchi, S. E., Guan, Y., Mallick, M., Xu, L., O’Neill, E. A., Williams‐Herman, D., Kaufman, K. D., & Goldstein, B. J. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12145 · Cited by 30
“Previously it was shown that sitagliptin inhibits glucagon secretion in acute experiments [14,15], and this study provides evidence that this is a persistent effect.”
BackgroundKennedy, L., & Peters, A. L. (2009) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.76.s5.04 · Cited by 32
Ridge, T., Moretto, T., MacConell, L., Pencek, R., Han, J., Schulteis, C. T., & Porter, L. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01639.x · Cited by 29
Self-citationClinical Implications of Exenatide as a Twice-Daily or Once-Weekly Therapy for Type 2 Diabetes
Aroda, V. R., & DeYoung, M. B. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.09.2479 · Cited by 27
“In contrast, GLP-1 agonists facilitate weight loss by slowing gastric emptying and decreasing food intake.(23,24) In the 24- and 30-week clinical studies with exenatide, patients were not given any special/additional guidance regarding nutrition or caloric restrictions.”
BackgroundExenatide Use in the Management of Type 2 Diabetes Mellitus
Kyriacou, A., & Ahmed, A. B. (2010) · Pharmaceuticals · doi:10.3390/ph3082554 · Cited by 28
“Two hours postprandial glucose, insulin and glucagon secretion, gastric emptying (assessed by acetaminophen absorption) and caloric intake were used as the study endpoint [19].”
MethodAlogliptin benzoate for the treatment of type 2 diabetes
Rendell, M., Drincic, A., & Andukuri, R. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.656088 · Cited by 27
“Administration of radioactively labeled alogliptin results in ~ 85% of plasma radioactivity, 95% of urine radioactivity and 88% of fecal radioactivity accounted for by the parent compound [44-46].”
BackgroundTong, Y., Huang, J., Chen, Y., Tu, M., & Wang, W. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1176206 · Cited by 27
“Furthermore, another GLP-1 RAs exenatide was also reported to have a slowing effect on gastric emptying (DeFronzo et al., 2008) and small intestine motility (Thazhath et al.”
BackgroundIn support of an early polypharmacy approach to the treatment of type 2 diabetes
Wright, E. E., Stonehouse, A. H., & Cuddihy, R. M. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01255.x · Cited by 27
“1 mmol/l, increased insulin secretion, reduced inappropriate glucagon secretion, reduced postprandial triglycerides, slowed gastric emptying and reduced caloric intake compared to sitagliptin [114].”
BackgroundDeFronzo, R. A., Triplitt, & Cersosimo (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s4852 · Cited by 27
Self-citationPharmacological Actions of Glucagon-Like Peptide-1, Gastric Inhibitory Polypeptide, and Glucagon
Sekar, R., Singh, K., Arokiaraj, A. W. R., & Chow, B. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.05.002 · Cited by 27
GLP-1-Based Strategies: A Physiological Analysis of Differential Mode of Action
Burcelin, R., Gourdy, P., & Dalle, S. (2014) · Physiology · doi:10.1152/physiol.00009.2013 · Cited by 26
“A short-term, 2-wk treatment with exenatide reduced postprandial glucagon in Type 2 diabetic patients (32).”
BackgroundStonehouse, A., Walsh, B., & Cuddihy, R. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0076 · Cited by 26
Ertuğlu, L. A., Porrini, E., Hornum, M., Demiray, A., Afşar, B., Ortíz, A., Covic, A. C., Rossing, P. R., & Kanbay, M. (2021) · Transplant International · doi:10.1111/tri.13883 · Cited by 26
“GLP-1 lowers postprandial blood glucose levels via augmenting insulin and suppressing glucagon secretions, slowing gastric emptying and inducing satiety [27,28].”
BackgroundWhat are the pharmacotherapy options for treating prediabetes?
Daniele, G., Abdul‐Ghani, M. A., & DeFronzo, R. A. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.944160 · Cited by 27
“3 DDP-4 inhibitors DDP-4, the enzyme that cleaves GLP-1 (and GIP), increases plasma GLP-1 levels but, because the increase in plasma GLP-1 level is highly dependent upon endogenous GLP-1 (and GIP) secretion, the magnitude of increase in plasma GLP-1 (and GIP) is quite modest compared to that achieved with GLP-1 recept…”
ResultSelf-citationCobble, M. E. (2012) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-4-8 · Cited by 26
“May improve markers of pancreatic b-cell function (such as homeostasis model assessment-b-cell function, fasting insulin, fasting proinsulin to insulin ratio, fasting C-peptide)[8,13,22-24,26,30] ✓ ✓”
BackgroundInfluentialOkimura, T., Jiang, Z., Liang, Y., Yamaguchi, K., & Oda, T. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.12.084 · Cited by 26
Hattori, S. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00533-3 · Cited by 25
Berg, J. K., Kim, E. H., Li, B. C., Joelsson, B. E., & Youssef, N. N. (2014) · BMC Gastroenterology · doi:10.1186/1471-230x-14-25 · Cited by 24
“However, the appearance of ingested acetaminophen in the plasma is an established and validated measure of gastric emptying kinetics [42] and has been used extensively in the analysis of GLP-1 receptor agonists [52-57].”
BackgroundBellin, M. D., Beilman, G. J., Dunn, T. B., Pruett, T. L., Sutherland, D. E. R., Chinnakotla, S., Hodges, J. S., Lane, A., Ptacek, P., Berry, K. L., et al. (2016) · American Journal of Transplantation · doi:10.1111/ajt.13979 · Cited by 24
“Furthermore, GLP-1 agonists such as exenatide may benefit glycemic control through delayed gastric emptying and suppression of postprandial glucagon, beneficial effects that may not occur with DPP-4 inhibitor therapy (45).”
Unger, J. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0470 · Cited by 23
“0011).(29) Exenatide demonstrated a significant slowing of gastric emptying compared with baseline and sitagliptin (P<.”
BackgroundResultBeyond Metformin: Initiating Combination Therapy in Patients with Type 2 Diabetes Mellitus
Goldman, J. D. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.12.44s · Cited by 23
Gatford, K. L., Sulaiman, S. A., Mohammad, S. N. B., Blasio, M. J. D., Harland, M. L., Simmons, R. A., & Owens, J. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056553 · Cited by 23
Cirincione, B. B., Edwards, J., & Mager, D. E. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9975-1 · Cited by 23
Green, J. (2010) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s6270 · Cited by 22
King, A. B., Montanya, E., Pratley, R. E., Blonde, L., Svendsen, C. B., Donsmark, M., & Sesti, G. (2012) · Endocrine Practice · doi:10.4158/ep12232.or · Cited by 22
Sanon, S., Patel, R., Eshelbrenner, C., Sanon, V. P., Alhaddad, M., OLIVEROS, R. A., Pham, S. V., & CHILTON, R. J. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.08.035 · Cited by 21
Kitahara, Y., Miura, K., Yasuda, R., Kawanabe, H., Ogawa, S., & Eto, Y. (2011) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.34.671 · Cited by 21
Metformin + saxagliptin for type 2 diabetes
Scheen, A. J. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.642867 · Cited by 21
The Effect of GLP-1 Receptor Agonists on Postprandial Lipaemia
Novodvorský, P., & Haluzík, M. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-00982-3 · Cited by 21
Medicinal Plants Qua Glucagon-Like Peptide-1 Secretagogue via Intestinal Nutrient Sensors
Kim, K., & Jang, H.-J. (2015) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2015/171742 · Cited by 21
“However, patients prescribed GLP-1 analogues have suffered needle phobia and side effects such as nausea, vomiting, and anorexia [13, 14].”
BackgroundFocus on Incretin-Based Therapies: Targeting the Core Defects of Type 2 Diabetes
Jellinger, P. S. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.01.2245 · Cited by 21
Zhang, S., Sidra, F. N. U., Álvarez, C. A., Kinaan, M., Lingvay, I., & Mansi, I. A. (2024) · Nature Communications · doi:10.1038/s41467-024-54009-3 · Cited by 20
“…control, body weight reductions, improved beta cell function,anddecreasedincidencehypoglycemiaascomparedtoDPP4iina general diabetes population 26 – 31 , effects which might explain the reduction of acute healthcare utilization observed in this study of patients with CKD treated with GLP1-RA as…”
The metabolic syndrome influences the response to incretin-based therapies
Fadini, G. P., de Kreutzenberg, S. V., Gjini, R., & Avogaro, A. (2011) · Acta Diabetologica · doi:10.1007/s00592-011-0296-7 · Cited by 20
“[5] found that exenatide was superior to sitagliptin in reducing post-prandial glucose in type 2 diabetic obese patients, many of which likely had MS.”
Metadata
- Authors
- DeFronzo, R. A., Okerson, T., Viswanathan, P., Guan, X., Holcombe, J. H., & MacConell, L.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Amylin Pharmaceuticals, Inc., San Diego, CA, USA
- Eli Lilly (United States) (US)
- Corresponding author
- DeFronzo, Ralph A.
- ORCID
- DeFronzo, Ralph A.
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa UK Limited
- Published
- 2008-09-10
- Volume
- 24
- Issue
- 10
- Pages
- 2943-2952
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2159198773
- Cited by
- 373
- References
- 33
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 8 · 2023: 3 · 2022: 6 · 2021: 11 · 2020: 14 · 2019: 7 · 2018: 12 · 2017: 19 · 2016: 20 · 2015: 23 · 2014: 38 · 2013: 36 · 2012: 40
- FWCI
- 30.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medical Research and Opinion (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- exenatide, sitagliptin, type 2 diabetes, postprandial blood glucose, insulin secretion, glucagon secretion, gastric emptying, energy intake, GLP-1 receptor agonists, DPP-4 inhibitors, insulinogenic index, metformin, glycemic control, drug comparison, fasting blood glucose
- MeSH terms
- Sitagliptin Phosphate, Exenatide, Insulin Secretion, Blood Glucose, Energy Intake, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glucagon, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, Peptides, Pyrazines, Stomach, Triazoles, Venoms, Cross-Over Studies, Postprandial Period
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.